System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Dr Björn-Erik Ole Jensen, MD, PhD is an expert in Infectiology at Düsseldorf University Hospital (Germany). As of October 2026, ScienceLeadR ranks Björn-Erik Ole Jensen in the top 1% of experts worldwide for Coronavirus Infections. Björn-Erik Ole Jensen has authored 75 publications, the most recent in 2026, and is an investigator in 7 clinical trials, 5 of them ongoing. SLR score: 308 (community average: 125). How the SLR is computed.

LeadR Profile

Dr Björn-Erik Ole Jensen, MD, PhD Düsseldorf University Hospital Germany
308 ScienceLeadR Reputation 308

Unlock

Register Login
Network Map

Infectiology

Subspecialties: Public Health - Hematology - Endocrinology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2014 - 2026
Source: PubMed

Heinrich Heine University Düsseldorf

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 75

Citations

Citations: 1 906 1st author: 1 Last author: 6 Unique author: 0

Main journals

Infection 19
J Infect Dis 3
Notf Rett Med 3
PLoS One 3
Clin Infect Dis 2

Best Journals

Nature 2
Lancet Digit Health 1
Nat Med 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Clinical characteristics and outcomes of localized versus disseminated nontuberculous mycobacterial disease in people living with HIV, 2004-2025.
PMID 42828631 — cd4 lymphocyte count, cells, mortality, mycobacterium, diagnosis, infections		Infection20260
ClinIAN: Clinically Informed Attention Network.
PMID 42775294 — infections		Bioinform Adv20260
First-Line PD-1 Inhibitor-Based Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Revised Systematic Review and Meta-Analysis of Phase III Trials.
PMID 42702772 — cells, carcinoma, squamous cell, neoplasms, drug therapy, biomarkers, immunotherapy, nivolumab, esophageal squamous cell carcinoma, therapeutics, chemotherapy		Cancer Rep (Hoboken)20260
Characterization of post-COVID syndrome by self-perceived symptom severity stratified by infection wave: beyond COVID, a prospective, multicenter cohort study in Germany.
PMID 42149360 — cohort studies, signs and symptoms, infections		Infection20260
Increased in-hospital mortality in immunocompromised individuals hospitalized with COVID-19 during the global pandemic, a multinational cohort study in the EuCARE project.
PMID 42100898 — mortality, vaccines, cohort studies, hospital mortality, vaccination, covid-19, pneumonia, pandemics, mediation analysis, communicable diseases		J Infect Dis20260

Clinical Studies 7

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

N/A 5
Phase 2 1
Phase 3 1

By status:

Recruiting 3
Unknown 2
Active not recruiting 1
Not yet recruiting 1

By type:

Observational 5
Interventional 2

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 2
multicentricup10 4

Main Topics

Cohort/Consortium Investigators 3

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
VIROMARKERS GA n 101194735 CMV and TTV Biomarkers Study Protocol
NCT07286461 — cells, blood, microscopy, electron, scanning transmission, suspensions, hematopoietic stem cell transplantation, polymerase chain reaction, stem cells, biomarkers, signs and symptoms, research, therapeutics, cell transplantation, stem cell transplantation, dna, hematopoietic stem cells, real-time polymerase chain reaction, transplantation, antiviral agents, infections, plasma		N/ANot yet recruiting2025
Proof of concept treatment study of orally administered VH4004280 or VH4011499 in HIV 1 infected adults
2023-505350-18-00 — hiv-1, safety, capsid, hiv, therapeutics, hiv infections, antiviral agents, infections, pharmacokinetics		Phase 2Active not recruiting2023
Health Care Workers Cohort Study in the EuCARE Project (EuCARE HCW)
NCT05534009 — immunization, vaccines, cohort studies, respect, vaccination, covid-19, immunity, diagnosis, records, infections		N/ARecruiting2022
Post COVID 19 Condition
NCT05531773 — blood, cohort studies, ambulatory care facilities, recycling, covid-19, physicians, physiatrists, cardiologists, outpatients, neurologists, communicable diseases		N/ARecruiting2022
Hospitalised COVID 19 Patients Cohort Study in the EuCARE Project
NCT05463380 — vaccines, cohort studies, covid-19		N/ARecruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS